Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

被引:0
作者
Åsa Ericsson
Adam Lundqvist
机构
[1] Novo Nordisk Scandinavia AB,
[2] IHE,undefined
[3] The Swedish Institute for Health Economics,undefined
来源
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词
Liraglutide; Insulin Glargine; Basal Insulin; Insulin Aspart; Insulin Detemir;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:237 / 248
页数:11
相关论文
共 157 条
[1]  
Stratton IM(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ. 321 405-412
[2]  
Adler AI(2008)Standards of medical care in diabetes: 2008 Diabetes Care. 31 S12-S54
[3]  
Neil HAW(2003)Hypoglycemia in diabetes Diabetes Care. 26 1902-1912
[4]  
Matthews DR(2008)How hypoglycaemia can affect the life of a person with diabetes Diabetes Metab Res. 24 87-92
[5]  
Manley SE(2014)Self-reported non-severe hypoglycaemic events in Europe Diabet Med. 31 92-101
[6]  
Cull CA(2012)DB4 patient-reported hypoglycaemia in real-world settings in seven European countries Value Health. 15 A277-198
[7]  
Cryer PE(2006)Cost of hypoglycemia in patients with Type 2 diabetes in Sweden Value Health. 9 193-853
[8]  
Davis SN(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33 Lancet. 352 837-73
[9]  
Shamoon H(2009)Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients Diabetologia. 52 65-57
[10]  
Frier BM(2008)The Swedish cost burden of overweight and obesity—evaluated with the PAR approach and a statistical modelling approach Int J Pediatr Obes. 3 51-689